Treatment of hepatitis C: Critical appraisal of the evidence

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 3, 2005, Pages 399-408

  Cammà, Calogero ^a,b,c   Licata, Anna ^a   Cabibbo, Giuseppe ^a   Latteri, Federica ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c NONE   (Italy)

Author keywords

Combination treatment; Hepatitis C; Histological benefit; Meta analysis; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ACUTE HEPATITIS; ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DATA ANALYSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXPERIMENTATION; GENOTYPE; HEALTH CARE ORGANIZATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONOTHERAPY; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PUBLICATION; RELAPSE; REVIEW; STANDARDIZATION; TREATMENT PLANNING;

ACUTE DISEASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS;

EID: 17144404226     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.3.399     Document Type: Review

References (44)

1. NIEDERAU C, LANGE S, HEINTGES T et al.: Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology (1998) 28:1687-1695.
2. FATTOVICH G, GIUSTINA G, DEGOS F et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 112: 463-472.
3. EL-SERANG HB, MASON AC: Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. (1999) 340 745-750.
4. PAGLIARO L, PERI V, LINEA C, CAMMA C, GIUNTA M, MAGRIN S: Natural history of chronic hepatitis C. Ital. J. Gastroenterol. Hepatol. (1999) 31:28-44.
5. DAVIS GL, BALART LA, SCHIFF ER et al.: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1989) 321:1501-1506.
6. FALCK-YTTER Y, KALE H, MULLEN KD, SARBAH SA, SORESCU L, MCCULLOUGH AJ: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann. Intern. Med. (2002) 136 288-292.
7. FRIED MW: Side effects of therapy of hepatitis C and their management. Hepatology (2002) 36:S237-S244.
8. SEEFF LB, HOOFNAGLE JH: National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 36:S1-S2.
9. ALBERTI ASB, VARIO A, BENVEGNÙ L: Therapy of acute hepatitis C. Hepatology (2002) 36:S195-S200.
10. LICATA A, DI BONA D, SCHEPIS F, SHAHIED L, CRAXI A, CAMMA C: When and how to treat acute hepatitis C? J. Hepatol. (2003) 39 1056-1062.
11. DI BISCEGLIE AM, HOOFNAGLE JH: Optimal therapy of hepatitis C. Hepatology (2002) 36:S121-S127.
12. HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. (2000) 343:1673-1680.
13. ZEUZEM S, FEINMAN SV, RASENACK J et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. (2000) 343:1666-1672.
14. LINDSAY KL, TREPO C, HEINTGES T et al.: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 34:395-403.
15. REDDY KR, WRIGHT TL, POCKROS PJ et al.: Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 33:433-438.
16. MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958-965.
17. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347:975-982.
18. HADZIYANNIS SJ, SETTE H JR, MORGAN TR et al.: and the PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. (2004) 140:346-355.
19. BRUNO S, CAMMA C, DI MARCO V et al.: Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J. Hepatol. (2004) 41:474-481.
20. HOURIGAN LF, MACDONALD GA, PURDIE D et al.: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 29:1215-1219.
21. RATZIU V, GIRAL P, CHARLOTTE F et al.: Liver fibrosis in overweight patients. Gastroenterology (2000) 118 1117-1123.
22. MCCULLOUGH AJ, FALCK-YTTER Y: Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology (1999) 29:1328-1330.
23. BRESSLER BL, GUINDI M, TOMLINSON G, HEATHCOTE J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology (2003) 38 639-644.
24. JEN J, LAUGHLIN M, CHUNG C et al.: Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Ther. (2002) 72:349-361.
25. MCHUTCHISON JG, GORDON SC, SCHIFF ER et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1998) 339:1485-1492.
26. POYNARD T, MARCELLIN P, LEE SS et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352:1426-1432.
27. BERNSTEIN D, KLEINMAN L, BARKER CM, REVICKI DA, GREEN J: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (2002) 35:704-708.
28. CUZICK J, EDWARDS R, SEGNAN N: Adjusting for non-compliance and contamination in randomized clinical trials. Stat. Med. (1997) 16:1017-1029.
29. GOETGHEBEUR EJ, SHAPIRO SH: Analysing non-compliance in clinical trials: ethical imperative or mission impossible? Stat. Med. (1996) 15:2813-2826.
30. DIENSTAG J: The role of liver biopsy in chronic hepatitis C. Hepatology (2002) 36(Suppl.):152-160.
31. CAMMA C, GIUNTA M, LINEA C, PAGLIARO L: The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J. Hepatol. (1997) 26 1187-1199.
32. CAMMA C, DI BONA D, SCHEPIS F et al.: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology (2004) 39 333-342.
33. POYNARD T, MCHUTCHISON J, MANNS M et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 122 1303-1313.
34. POYNARD T, MCHUTCHISON J, DAVIS GL et al.: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 32 1131-1171.
35. YUEN MF, CHENG CC, LAUDER IJ, LAM SK, OOI CG, LAI CL: Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology (2000) 31:330-335.
36. BRUIX J, LLOVET JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 35 519-524.
37. LLOVET JM, BURROUGHS A, BRUIX J: Hepatocellular carcinoma. Lancet (2003) 362:1907-1917.
38. LLOVET JM, FUSTER J, BRUIX J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 30:1434-1440.
39. LIPPMAN SM, HONG WK: Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al.: Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res. (2002) 8:305-313.
40. DE BAC C, STROFFOLINI T, GAETA GB, TALIANI G, GIUSTI G: Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology (1994) 20 1442-1449.
41. SPORN MB, DUNLOP NM, NEWTON DL, SMITH JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. (1976) 35:1332-1338.
42. CAMMÀ C, GIUNTA M, ANDREONE P, CRAXÌ A: Interferon and prevention of hepatocellular carcinoma: an evidence-based approach. J. Hepatol. (2001) 34:593-602.
43. NISHIGUCHI S, KUROKI T, NAKATANI S et al.: Randomised trial of effects of interferon-e on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 346 1051-1055.
44. SOFIA S, CASALI A, BUSCARINI E et al.: Effect of lymphoblastoid IFN in the treatment of liver cirrhosis and prevention of HCC. Ital. J. Gastroenterol. Hepatol. (1998) 30:A31.